NovaScan is a Chicago-based clinical-stage oncology company building low-cost, point-of-care devices that detect cancer in real time. Its platform pairs spectral bioimpedance with machine learning around a single biophysical signal - the Cole relaxation frequency, which differs by orders of magnitude between cancerous and healthy tissue. Two lead products, nsCanary for assessing biopsy cores and MarginScan for checking surgical excision margins, aim to deliver answers in seconds instead of the days that conventional pathology can take.
Peter Martin is the co-founder, President and CEO of Siesta Medical, a Los Gatos medical device company building minimally invasive treatments for obstructive sleep apnea that need no masks and no machines. Since 2009 he has guided the company from an idea to FDA-cleared products - the Encore System, the Revolution Suture Passer and the AIRLIFT hyoid suspension procedure - that reposition the airway with two small implants and a stitch. A Duke and Stanford trained mechanical engineer, he spent 15-plus years in medical device operations before turning Siesta into one of the most-cited names in surgical sleep apnea care.
R. Scott Jones is the Chairman and CEO of Intravascular Imaging Incorporated (i3), a Wilton, Connecticut medtech startup commercializing a 3-French NIRF-IVUS catheter that lets cardiologists see both the anatomy and the biology of a diseased coronary artery in a single pass. A medical device operator with more than 25 years in the field, he once ran GE Medical Systems' cardiovascular business across the Americas and Asia and has steered companies from two-person startups to organizations of 7,000 employees. At i3 he is the commercial engine behind a technology born in the labs of Massachusetts General Hospital and the Technical University of Munich.
Robert K. Weigle is a medical device and diagnostics executive with more than 25 years of experience taking healthcare products from pre-clinical research to commercial launch. He is CEO of NOW Diagnostics, an independent board member of Tenon Medical, and a former entrepreneur-in-residence at DigitalDx Ventures. He led Benvenue Medical as CEO for over a decade, raising more than $200 million and launching spine devices in two markets, and later ran saliva-based diagnostics companies focused on cancer detection. His career spans Fortune 500 names like Johnson & Johnson and Baxter as well as a string of venture-backed startups.
Axion Ray (operating as Axion) builds an AI 'observability command center' that helps the world's largest manufacturers catch product quality and safety problems months before they turn into recalls. Founded in 2021 by former McKinsey AI strategist Daniel First, the company fuses fragmented, unstructured field data - service tickets, dealership notes, call-center transcripts, sensor telemetry - into early-warning intelligence for engineering teams. Backed by Bessemer Venture Partners, RTX Ventures, Amplo and Inspired Capital with $25M raised, Axion works with manufacturers across aerospace, automotive, medtech and consumer goods.
Beacon Biosignals is a Boston-based neurotechnology company that pairs FDA-cleared wearable EEG hardware with AI to turn brain electrical activity - especially during sleep - into scalable, at-home neurodiagnostics. Its platform powers drug development, clinical trials, and precision medicine across neurology, psychiatry, and sleep medicine.
Shawn O'Neil is the CEO of ViaLase, a clinical-stage medtech company building FLIGHT, an incision-free femtosecond laser procedure for glaucoma. He spent more than two decades at Alcon rising to head of sales and marketing for surgical glaucoma, then ran commercial at Sight Sciences before joining ViaLase as Chief Commercial Officer and stepping up to CEO in July 2025. His career has been a running tour of the products that reshaped eye surgery: EX-PRESS, LenSx, CyPass, OMNI, TearCare, and now a laser that treats glaucoma without ever touching the eye with a blade.
Thomas (Tom) Arnold is the Chief Executive Officer of ViCentra, the Dutch maker of Kaleido, billed as one of the smallest, lightest and most precise insulin patch pumps in its class. Appointed in February 2025 after nearly 25 years across Medtronic, PROCEPT BioRobotics, Boston Scientific and Sorin Group, he is steering ViCentra's smartphone-controlled automated insulin delivery system into European markets and toward a US entry, backed by financing that has grown from $85M to $98M.
Sungwoo Min is the founder and CEO of Nventric, Inc., an Arcadia, California medical device company that designs, develops, and contract-manufactures vascular devices for the neurovascular, electrophysiology, and coronary markets. A Stanford-trained mechanical engineer who cut his teeth on R&D and marketing at Abbott Vascular and later led R&D programs at Johnson & Johnson, he started Nventric in 2019 to build the kind of life-saving catheters, stents, and thrombectomy systems he used to ship at the giants - this time end to end, ISO 13485 certified, with operations in the US and South Korea. He is a named inventor on multiple US patents for mechanical thrombectomy devices.
William G. Hendren, MD, MBA is the co-founder and CEO of QURA, Inc., a Duxbury, Massachusetts medical technology company building the QSmart platform - an implantable biosensor roughly the size of a grain of rice that continuously measures and wirelessly transmits medical-grade blood pressure data in real time. A surgeon trained at Harvard, Mass General, Emory and the Cleveland Clinic, with an MBA and strategic healthcare consulting experience at PwC across the US, Middle East, China and the UK, Hendren is taking aim at hypertension, which he calls the single leading healthcare threat in the world.
Marissa Fayer is a 25-year medtech executive who runs DeepLook Medical, an AI diagnostics company that helps radiologists spot breast cancer earlier in women with dense breast tissue, which she took from concept through FDA clearance into global commercialization. She is also the founder of HERhealthEQ, a nonprofit that has reached over 128,000 women across 12 countries by deploying medical devices for cancers, maternal health, and cardiovascular disease. A partner at women's-health fund Goddess Gaia Ventures and author of the forthcoming book 'Undervalued to Unavoidable,' she argues women's health is not a charitable cause but economic infrastructure that has been systematically underestimated.
Caresyntax is an AI-powered surgical intelligence platform that turns the operating room into a connected data environment. Its vendor-neutral software captures video, device, and EMR data across more than 4,000 ORs and supports over two million procedures a year, helping hospitals improve outcomes, reduce costs, and make surgery measurably safer.
Daedalus is an AI-driven precision manufacturing company building software-defined factories that produce high-precision parts for defense, medtech, semiconductors and industrial customers. Founded by former OpenAI Robotics technical lead Jonas Schneider, the company pairs off-the-shelf CNC hardware with its proprietary Manufacturing AI Platform to automate the work that traditionally requires veteran machinists - quoting, process planning, machine control and quality inspection - and runs it all out of a 50,000-square-foot factory in Karlsruhe, Germany.
Hawthorne Health is a clinical trials company that decentralizes research by sending GCP-trained medical professionals - called Hawthorne Heroes - directly into patients' homes, pharmacies, and community settings. Founded in 2015 by former Edwards Lifesciences executive Jodi Akin, the company operates the largest mobile nurse network in clinical research, covering 50+ states and territories, with access to over 1,000 community-based locations. Their technology platform and distributed workforce model have completed 76+ trials with a 99% visit completion rate while achieving patient diversity metrics 3-10x above industry standards.
David Schummers is the co-founder and CEO of Apella Technology, a San Francisco-based ambient AI company transforming how hospitals run their operating rooms. Using computer vision and machine learning, Apella captures real-time surgical intelligence - automatically documenting up to 14 case events per procedure and feeding structured data back into EHR systems - reducing OR turnover times by 16% and increasing case volume by 10%. Before founding Apella in 2019, Schummers spent two decades in health technology, including a pivotal stint at Auris Health as its first commercial executive, where he helped engineer the company's $5.7 billion acquisition by Johnson & Johnson in 2019 - at the time the largest medical technology startup transaction in history. Apella raised an $80 million Series B in January 2026 led by HighlandX, bringing total funding to over $104 million.
Jonas Schneider is the Founder and CEO of Daedalus, an AI-powered precision manufacturing company headquartered in Karlsruhe, Germany, building the factory of the future. A former OpenAI technical lead and co-founder of its robotics team, Schneider left Silicon Valley in 2019 to solve a problem he lived firsthand: getting precision-manufactured parts takes months, and the world's most advanced machines sit idle 80% of the time. Daedalus deploys proprietary AI software across CNC shop floors to double machine utilization, catch defects in real time, and preserve tacit manufacturing knowledge before it disappears with retiring machinists. The company has raised $41.1M in total funding, including a $21M Series A led by NGP Capital in February 2024, and operates a 50,000-square-foot factory serving defense, medical devices, aerospace, and semiconductor clients.
Josh Rose is the CEO of Hawthorne Health, Inc. (formerly Hawthorne Effect), a Walnut Creek-based company building the largest community-based clinical trial site network in the U.S. A clinical research industry veteran with over 20 years of experience, Rose previously led decentralized clinical trial strategy at IQVIA and CVS Health before taking the helm at Hawthorne Health in early 2024. Under his leadership, Hawthorne has expanded to 75+ community locations, partnered with 40+ pharma sponsors, and pioneered a model that embeds certified clinical research staff inside independent pharmacies and patients' homes - bringing trials to communities that traditional research networks have long bypassed.
Keith Carter is a healthcare technology operator with deep roots in medical imaging and surgical data infrastructure. Currently VP of Implementations & Integrations at Caresyntax - the AI-powered surgical intelligence platform used in 3,500+ operating rooms worldwide - he also serves as CEO of Cloud9PACS.com, a digital PACS system he built from the ground up. Carter's career traces the arc of healthcare IT: from PACS architect at Medlink to running his own imaging solutions company, to joining one of the most-funded surgical AI ventures in the industry. He is based in Hattiesburg, Mississippi.
Ken Kaufman is the CEO of Sirona Medical, a San Francisco-based cloud-native radiology platform backed by $118M in funding. A radiology IT veteran with decades of experience at IDX Systems, McKesson, and Allscripts, he co-founded PureWellness — a population health platform that grew to 15 million users and was acquired by Cerner in 2013. Now at Sirona, he is driving the company's mission to rearchitect radiology software with AI at its core, helping radiologists read faster, practice everywhere, and generate reports with unprecedented efficiency.
Matt Krueger is the Chief Executive Officer of Caresyntax, an AI-powered surgical intelligence platform used in 4,200+ operating rooms worldwide and supporting over 3 million surgical procedures annually. A decade-long veteran of the company, Krueger rose through roles including SVP & GM for the Americas & ANZ, Chief Commercial Officer, Chief Customer Officer, and President before being elevated to CEO in July 2025. With 18+ years in medical devices and healthcare technology - including stints at Hill-Rom and TRUMPF - he has been a primary architect of Caresyntax's expansion and its consistent 50%+ organic revenue growth trajectory.
Nichole Garcia is Co-Founder and President of OrthoFX, the doctor-delivered clear aligner startup she built with two former Invisalign executives. With a BS in Biochemistry from UCLA, an MBA from Pepperdine, and a diploma from Oxford, she spent two decades running global divisions at Philips Oral Care and Align Technology before co-founding OrthoFX in 2017. The company raised $17M total - including a $13M Series A led by SignalFire in 2020 - to commercialize a proprietary FXTetra polymer that delivers 50% faster treatment, paired with an AI-powered remote monitoring platform called FXOnTrack.
Ren Menon is the cofounder and CEO of OrthoFX, a Fremont-based dental technology company reinventing clear aligner therapy. A former Invisalign executive with over two decades in the clear aligner space, Menon launched OrthoFX in 2019 with co-founders from Align Technology and Philips Oral Care to offer doctor-delivered, AI-monitored clear aligners at roughly half the cost of Invisalign. The company has raised $17 million across three rounds - most recently a $13M Series A led by SignalFire - and has developed proprietary polymer technology including its HyperElastic FXTetra material and the FDA-cleared AirFlex aligner system. OrthoFX operates a hybrid D2C/B2B model, combining direct consumer access with professional orthodontist delivery, underpinned by the FXOnTrack AI platform for remote patient monitoring.
VuMedi is the largest healthcare video education platform - a YouTube-style network built for doctors, by doctors. Founded in 2008 by Roman Giverts, it now serves more than 600,000 physicians across 20+ specialties with peer-reviewed clinical videos, lectures, and discussions produced with hospitals like Cleveland Clinic, Mayo Clinic, Stanford and NYU.
Promaxo builds the world's first single-sided, in-office MRI platform - a compact magnet, AI, and robotics stack that lets urologists run image-guided prostate biopsies and focal treatments in their own clinic, without a hospital scanner suite.
Genevieve Lemarchal is the Managing Partner of Suncoast Ventures and Head of Healthcare at Expert Dojo, one of Southern California's most active pre-seed venture funds. A serial entrepreneur turned investor, she focuses on early-stage healthcare startups tackling critical gaps in addiction recovery, maternal care, chronic disease management, and digital health. With a portfolio spanning 35+ companies across 7 countries, she champions underrepresented founders - 50% female, 37-43% from underrepresented backgrounds - and hosts the AdVentureous Podcast, where she interviews entrepreneurs and VCs about building companies that matter.
Yatin Mundkur is a General Partner at Artiman Ventures, a Palo Alto-based early-stage venture fund with over $1 billion under management. With 25+ years spanning semiconductor design, founding a company, and two decades of VC investing, he holds 14 patents and has backed companies through 14 IPOs and 38 acquisitions. He also serves as CEO of Cellworks Group, applying his engineering roots to precision medicine.
John Balen is a General Partner at Canaan Partners, one of the oldest venture capital firms in the US, where he has been investing since 1995. With a background in electrical engineering and an MBA from Cornell University, he brings both operational and financial depth to early-stage investing across consumer internet, fintech, enterprise software, medtech, and digital health. His portfolio includes companies that have gone public (Cardlytics, Commerce One, eStamp) and been acquired by major players including Akamai, Dell, Expedia, and Oracle. He resides in Hillsborough, California, and is an active Cornell trustee and mentor.
Jonathan Root is a General Partner at U.S. Venture Partners (USVP) in Menlo Park, California, where he has invested in early-stage companies since 1997. A board-certified neurologist who spent nine years in clinical medicine - including as a Director of the Neurology-Neurosurgery ICU at New York Hospital-Cornell Medical Center - Root brings a rare clinician's lens to venture investing. He focuses on medical devices, biotech, and healthcare IT, with a portfolio that spans Omada Health, Carlsmed, Cleave Biosciences, and Inari Medical (acquired by Stryker in 2025). His guiding principle: 'The greatest idea in the world will not be successful if it's not practical.'
Joydeep Bhattacharyya is a General Partner at Canaan Partners, a leading venture capital firm, where he focuses on enterprise and cloud platform investments - particularly in cybersecurity and automation. A former Microsoft engineer who helped shape Office 365 and Skype for Business, and a one-time enterprise investor at Shasta Ventures, he brings deep operational and strategic experience to early-stage companies. An immigrant from India, he is a known advocate for international founders navigating the U.S. startup ecosystem. His portfolio includes companies like Dragos, Snyk, Human Security, MindTickle, and Contentsquare. Outside the boardroom, he plays the sitar, roots for the Indian cricket team, and co-founded a rural welfare initiative in India.
Julie Grant is a General Partner at Canaan, a $5B technology and healthcare venture capital firm, where she leads biopharma investments and company formation on the West Coast. She co-founded and served as founding CEO of Day One Biopharmaceuticals, a purpose-built pediatric oncology company that grew to a $1.5B+ valuation and was later acquired by Servier. A Yale-educated molecular biophysicist who went on to Stanford MBA and Cambridge MPhil, Grant brings rare operational depth to venture - having sat in the CEO chair before returning to investing. In 2023, President Biden appointed her to the National Cancer Advisory Board. She is the fourth woman to become a General Partner at Canaan.